Russia's RDIF rejects Brazilian regulator Anvisa's comments about Sputnik V as 'incorrect'

1 minute read

MOSCOW, April 27 (Reuters) - The Russian Direct Investment Fund (RDIF) on Tuesday said comments about the Sputnik V COVID-19 vaccine from Brazilian health regulator Anvisa were incorrect and that a decision to delay the vaccine's approval could be politically motivated.

Anvisa on Monday rejected importing the Russian-made vaccine requested by state governors battling a deadly second wave of the virus that is battering Latin America's largest nation, saying technical staff had highlighted "inherent risks" and "serious" defects. read more

Register now for FREE unlimited access to
Reporting by Polina Ivanova; Writing by Alexander Marrow; Editing by Louise Heavens

Our Standards: The Thomson Reuters Trust Principles.

More from Reuters